Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery

NCT00991952 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Stage IIIA Gastric Cancer
Stage IIIB Gastric Cancer
Stage IIIC Gastric Cancer
Stage IV Gastric Cancer

Interventions

DRUG: alvocidib
DRUG: irinotecan hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)